If approved, Eyenovia will have the first microdosed
treatment for progressive myopia in the United States.
Prevention of Myopia Progression
MicroPineTM is our proprietary microdose formulation of atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children. Moderate-to-severe myopia is associated with a change to the shape of the eye. This change can lead to significant back-of-the eye problems, including retinal detachment, choroidal and retinal atrophy, and choroidal neovascularization, all of which can lead to permanent vision loss. 1. In the US alone, there are approximately 5 million children with myopia and many times more that number in Asia.
We believe Eyenovia’s delivery technology is particularly well-suited for this application, potentially enabling children to easily self-administer medication while minimizing dose-related side effects.
1. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641.
Watch his nighttime routine
Low-dose Atropine and Myopia Progression
There is clinical evidence for the use of low-dose atropine as a way to prevent progressive myopia in children.2 At Eyenovia, we believe that microdosed atropine could provide similar efficacy, while our Optejet™ dispenser could provide additional usability, safety, tolerability and compliance benefits for children.
2. Chua, W., Balakrishnan, V., Chan, Y., Tong, L., Ling, Y., Quah, B., & Tan, D. (2006). Atropine for the Treatment of Childhood Myopia. Ophthalmology, 113(12), 2285-2291. doi:10.1016/j.ophtha.2006.05.062.
On-Demand Vision Improvement
in Patients with Presbyopia
MicroLine is our proprietary pilocarpine formulation and candidate for the episodic treatment of presbyopia. We plan to begin our VISION Phase III study in 2020.
Pilocarpine has been demonstrated to constrict the pupil of the eye and create a “pinhole” effect, which like a pinhole camera, works to bring near and medium-distance objects into focus. This pinhole approach has been used in contact lenses and surgical approaches for presbyopia to improve near vision in patients with presbyopia, and now with MicroLine, Eyenovia looks towards improving near vision with it’s microdosed drug.
How The Pinhole Effect Focuses Light
© 2019 Eyenovia, Inc.
Learn more about our VISION Study
We plan to begin and complete our VISION study in 2020. We believe the study will open a new treatment paradigm for those who have presbyopia and provide eye care practitioners with a new treatment for improving their patients’ quality of life.
Making the annual eye exam quick and comfortable.
MicroStatTM is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation). Almost everyone who has had an eye examination has been treated with these drugs – there are an estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the US.3 Eyenovia’s delivery technology is intended to make this part of the exam both faster and more comfortable for patients, by reducing the number of doses for dilation and potentially minimizing dose-related side effects (including the need to wipe away excess drug that may fall out of the eye).
3. Fernando A. Wilson, Jim P. Stimpson, and Yang Wang, “Inconsistencies Exist in National Estimates of Eye Care Services Utilization in the United States,” Journal of Ophthalmology, vol. 2015, Article ID 435606, 4 pages, 2015. https://doi.org/10.1155/2015/435606.
Learn more about our Mist-1 & 2 Study
We’re placing the power of microdosing technology in the hands of physicians and technicians. Our Mist-1 & 2 study results were presented at the ASCRS 2019 annual meeting. These results showed the efficacy and safety of the fixed combination microdose formulation and the potential for offices to improve their patient flow. Eyenovia expects to file the NDA for it’s MicroStat product in 2020.